Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1111/j.1476-5381.2009.00617.x http://repositorio.unifesp.br/handle/11600/32293 |
Resumo: | Background and purpose:The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis.Experimental approach:BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. the animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund's adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines.Key results:Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than 'free' P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung.Conclusions and implications:Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect. |
id |
UFSP_4690bb2731a20ff95913d815650e6737 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/32293 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosisimmunomodulatory peptideantifungal therapybiodegradable polymersdrug deliverynanobiotechnologyBackground and purpose:The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis.Experimental approach:BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. the animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund's adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines.Key results:Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than 'free' P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung.Conclusions and implications:Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect.Univ Brasilia, Dept Biol Celular, Mol Biol Lab, Inst Biol Sci, BR-70910900 Brasilia, DF, BrazilUniv Brasilia, Inst Phys, BR-70910900 Brasilia, DF, BrazilUniv Catolica Brasilia, Brasilia, DF, BrazilUniv São Paulo, Inst Chem, BR-14049 Ribeirao Preto, BrazilUniv São Paulo, Inst Biomed Sci, São Paulo, BrazilUniv São Paulo, Med Mycol Lab, LIM53, MTSP, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilWeb of ScienceConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Wiley-BlackwellUniversidade de Brasília (UnB)Univ Catolica BrasiliaUniversidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)Amaral, Andre C.Marques, Alexandre F.Munoz, Julian E.Bocca, Anamelia L.Simioni, Andreza R.Tedesco, Antonio C.Morais, Paulo C.Travassos, Luiz Rodolpho [UNIFESP]Taborda, Carlos Pelleschi [UNIFESP]Felipe, Maria Sueli S.2016-01-24T13:59:21Z2016-01-24T13:59:21Z2010-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion1126-1132http://dx.doi.org/10.1111/j.1476-5381.2009.00617.xBritish Journal of Pharmacology. Malden: Wiley-Blackwell Publishing, Inc, v. 159, n. 5, p. 1126-1132, 2010.10.1111/j.1476-5381.2009.00617.x0007-1188http://repositorio.unifesp.br/handle/11600/32293WOS:000275402000014engBritish Journal of Pharmacologyinfo:eu-repo/semantics/openAccesshttp://olabout.wiley.com/WileyCDA/Section/id-406071.htmlreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2022-11-04T15:08:28Zoai:repositorio.unifesp.br/:11600/32293Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652022-11-04T15:08:28Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis |
title |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis |
spellingShingle |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis Amaral, Andre C. immunomodulatory peptide antifungal therapy biodegradable polymers drug delivery nanobiotechnology |
title_short |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis |
title_full |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis |
title_fullStr |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis |
title_full_unstemmed |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis |
title_sort |
Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis |
author |
Amaral, Andre C. |
author_facet |
Amaral, Andre C. Marques, Alexandre F. Munoz, Julian E. Bocca, Anamelia L. Simioni, Andreza R. Tedesco, Antonio C. Morais, Paulo C. Travassos, Luiz Rodolpho [UNIFESP] Taborda, Carlos Pelleschi [UNIFESP] Felipe, Maria Sueli S. |
author_role |
author |
author2 |
Marques, Alexandre F. Munoz, Julian E. Bocca, Anamelia L. Simioni, Andreza R. Tedesco, Antonio C. Morais, Paulo C. Travassos, Luiz Rodolpho [UNIFESP] Taborda, Carlos Pelleschi [UNIFESP] Felipe, Maria Sueli S. |
author2_role |
author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade de Brasília (UnB) Univ Catolica Brasilia Universidade de São Paulo (USP) Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Amaral, Andre C. Marques, Alexandre F. Munoz, Julian E. Bocca, Anamelia L. Simioni, Andreza R. Tedesco, Antonio C. Morais, Paulo C. Travassos, Luiz Rodolpho [UNIFESP] Taborda, Carlos Pelleschi [UNIFESP] Felipe, Maria Sueli S. |
dc.subject.por.fl_str_mv |
immunomodulatory peptide antifungal therapy biodegradable polymers drug delivery nanobiotechnology |
topic |
immunomodulatory peptide antifungal therapy biodegradable polymers drug delivery nanobiotechnology |
description |
Background and purpose:The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis.Experimental approach:BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. the animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund's adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines.Key results:Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than 'free' P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung.Conclusions and implications:Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-03-01 2016-01-24T13:59:21Z 2016-01-24T13:59:21Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1111/j.1476-5381.2009.00617.x British Journal of Pharmacology. Malden: Wiley-Blackwell Publishing, Inc, v. 159, n. 5, p. 1126-1132, 2010. 10.1111/j.1476-5381.2009.00617.x 0007-1188 http://repositorio.unifesp.br/handle/11600/32293 WOS:000275402000014 |
url |
http://dx.doi.org/10.1111/j.1476-5381.2009.00617.x http://repositorio.unifesp.br/handle/11600/32293 |
identifier_str_mv |
British Journal of Pharmacology. Malden: Wiley-Blackwell Publishing, Inc, v. 159, n. 5, p. 1126-1132, 2010. 10.1111/j.1476-5381.2009.00617.x 0007-1188 WOS:000275402000014 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
British Journal of Pharmacology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess http://olabout.wiley.com/WileyCDA/Section/id-406071.html |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://olabout.wiley.com/WileyCDA/Section/id-406071.html |
dc.format.none.fl_str_mv |
1126-1132 |
dc.publisher.none.fl_str_mv |
Wiley-Blackwell |
publisher.none.fl_str_mv |
Wiley-Blackwell |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268320521650176 |